![](/img/cover-not-exists.png)
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Diane M Harper, Eduardo L Franco, Cosette M Wheeler, Anna-Barbara Moscicki, Barbara Romanowski, Cecilia M Roteli-Martins, David Jenkins, Anne Schuind, Sue Ann Costa Clemens, Gary DubinVolume:
367
Year:
2006
Language:
english
DOI:
10.1016/s0140-6736(06)68439-0
File:
PDF, 134 KB
english, 2006